<p>加利福尼亞州瓦倫西亞，2026 年 2 月 13 日（全球新聞通訊）—— AVITA Medical, Inc.（ASX: AVH，NASDAQ: RCEL），一家領先的急性創傷護理公司，提供變革性解決方案，邀請股東和潛在投資者參加其投資者網絡研討會，由臨時首席執行官 Cary Vance 和首席財務官 David O’Toole 於 2026 年 2 月 18 日下午 2:00（太平洋標準時間）（2026 年 2 月 19 日上午 9:00，澳大利亞東部夏令時間）進行簡報和演示。</p>
<p>網絡研討會的演示將涵蓋 AVITA Medical 最近的 2025 財年第四季度和全年財務及業務結果，並以問答環節結束。參與者被邀請通過註冊頁面提交他們的問題。</p>
<p>要註冊參加演示，請點擊此 Zoom 鏈接：</p>
<p>https://us06web.zoom.us/webinar/register/WN_F_ldbJWLS1SQqUKIjfwFWQ</p>
<p>重播將在 AVITA Medical 網站上提供，網址為：https://ir.avitamedical.com/</p>
<p><strong>關於 AVITA Medical, Inc.</strong></p>
<p>AVITA Medical®是一家領先的急性創傷護理公司，提供變革性解決方案。我們的技術旨在優化傷口癒合，有效加速患者恢復的時間。我們平台的核心是 RECELL®，已獲得 FDA 批准用於治療熱燒傷和創傷性傷口。RECELL 利用患者自身皮膚的癒合特性，創造出噴霧皮膚™，為改善臨牀結果提供創新解決方案。在美國，AVITA Medical 還擁有製造、營銷、銷售和分銷 PermeaDerm®（一種生物合成傷口基質）的獨家權利，以及營銷、銷售和分銷 Cohealyx™（AVITA Medical 品牌的膠原基真皮基質）的獨家權利。</p>
<p>在國際市場上，RECELL 已獲批准用於促進廣泛應用的皮膚癒合，包括熱燒傷和創傷性傷口。RECELL 和 RECELL GO®已在歐洲獲得 CE 標誌；RECELL 在澳大利亞註冊為 TGA，並在日本獲得 PMDA 批准。</p>
<p>要了解更多信息，請訪問 www.avitamedical.com。</p>
<p><strong>投資者與媒體聯繫：</strong></p>
<p>Ben Atkins</p>
<p>電話 +1-805 341 1571</p>
<p>investor@avitamedical.com</p>
<p>media@avitamedical.com</p>
<p>經 AVITA Medical, Inc.首席財務官授權發佈。</p>
<p>©2026 AVITA Medical。AVITA Medical®、Cohealyx®、RECELL®、RECELL GO®和噴霧皮膚 TM 是 AVITA Medical 的商標。PermeaDerm®是 Stedical Scientific, Inc.擁有的註冊商標。所有其他商標均為其各自所有者的財產。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU5ETTJOU00zTkRJMU1UVTJJekl4T0RFMU1UQT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU5ETTJOU00zTkRJMU1UVTJJekl4T0RFMU1UQT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2MzNTMyMDYtMmJjYS00N2JiLWFiNWYtNDQ5M2E4ZTk0MGI4LTExOTMwNzktMjAyNi0wMi0xMy1lbg==/tiny/AVITA-Medical.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2MzNTMyMDYtMmJjYS00N2JiLWFiNWYtNDQ5M2E4ZTk0MGI4LTExOTMwNzktMjAyNi0wMi0xMy1lbg==/tiny/AVITA-Medical.png"/></p>

RCEL

<p>AVITA Medical, Inc. 將於 2026 年 2 月 18 日下午 2:00（太平洋標準時間）舉辦投資者網絡研討會，屆時將有臨時首席執行官 Cary Vance 和首席財務官 David O’Toole 出席。會議將討論公司 2025 年第四季度和全年財務業績，隨後進行問答環節。參與者可以通過提供的 Zoom 鏈接進行註冊。AVITA Medical 專注於急性創傷護理解決方案，包括獲得 FDA 批准的用於皮膚癒合的 RECELL 技術</p>

<p>VALENCIA, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, Interim Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 18, 2026, at 2:00 p.m. Pacific Standard Time (February 19, 2026, at 9:00 a.m. Australian Eastern Daylight Time).</p>
<div class="lb-trans"><p>加利福尼亞州瓦倫西亞，2026 年 2 月 13 日（全球新聞通訊）—— AVITA Medical, Inc.（ASX: AVH，NASDAQ: RCEL），一家領先的急性創傷護理公司，提供變革性解決方案，邀請股東和潛在投資者參加其投資者網絡研討會，由臨時首席執行官 Cary Vance 和首席財務官 David O’Toole 於 2026 年 2 月 18 日下午 2:00（太平洋標準時間）（2026 年 2 月 19 日上午 9:00，澳大利亞東部夏令時間）進行簡報和演示。</p>
</div><p>The webinar presentation will cover financial and business results from AVITA Medical’s recent fourth-quarter and full-year 2025 earnings webcast and will conclude with a Q&amp;A session. Participants are invited to submit their questions via the registration page.</p>
<div class="lb-trans"><p>網絡研討會的演示將涵蓋 AVITA Medical 最近的 2025 財年第四季度和全年財務及業務結果，並以問答環節結束。參與者被邀請通過註冊頁面提交他們的問題。</p>
</div><p>To register for the presentation, please follow this Zoom link:</p>
<div class="lb-trans"><p>要註冊參加演示，請點擊此 Zoom 鏈接：</p>
</div><p>https://us06web.zoom.us/webinar/register/WN_F_ldbJWLS1SQqUKIjfwFWQ</p>
<div class="lb-trans"><p>https://us06web.zoom.us/webinar/register/WN_F_ldbJWLS1SQqUKIjfwFWQ</p>
</div><p>A replay will be available on the AVITA Medical website at: https://ir.avitamedical.com/</p>
<div class="lb-trans"><p>重播將在 AVITA Medical 網站上提供，網址為：https://ir.avitamedical.com/</p>
</div><p><strong>About AVITA Medical, Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 AVITA Medical, Inc.</strong></p>
</div><p>AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL®, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.</p>
<div class="lb-trans"><p>AVITA Medical®是一家領先的急性創傷護理公司，提供變革性解決方案。我們的技術旨在優化傷口癒合，有效加速患者恢復的時間。我們平台的核心是 RECELL®，已獲得 FDA 批准用於治療熱燒傷和創傷性傷口。RECELL 利用患者自身皮膚的癒合特性，創造出噴霧皮膚™，為改善臨牀結果提供創新解決方案。在美國，AVITA Medical 還擁有製造、營銷、銷售和分銷 PermeaDerm®（一種生物合成傷口基質）的獨家權利，以及營銷、銷售和分銷 Cohealyx™（AVITA Medical 品牌的膠原基真皮基質）的獨家權利。</p>
</div><p>In international markets, RECELL is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds. RECELL and RECELL GO® have received the CE mark in Europe; and RECELL is TGA-registered in Australia, and has PMDA approval in Japan.</p>
<div class="lb-trans"><p>在國際市場上，RECELL 已獲批准用於促進廣泛應用的皮膚癒合，包括熱燒傷和創傷性傷口。RECELL 和 RECELL GO®已在歐洲獲得 CE 標誌；RECELL 在澳大利亞註冊為 TGA，並在日本獲得 PMDA 批准。</p>
</div><p>To learn more, visit www.avitamedical.com.</p>
<div class="lb-trans"><p>要了解更多信息，請訪問 www.avitamedical.com。</p>
</div><p><strong>Investor &amp; Media Contact:</strong></p>
<div class="lb-trans"><p><strong>投資者與媒體聯繫：</strong></p>
</div><p>Ben Atkins</p>
<div class="lb-trans"><p>Ben Atkins</p>
</div><p>Phone +1-805 341 1571</p>
<div class="lb-trans"><p>電話 +1-805 341 1571</p>
</div><p>investor@avitamedical.com</p>
<div class="lb-trans"><p>investor@avitamedical.com</p>
</div><p>media@avitamedical.com</p>
<div class="lb-trans"><p>media@avitamedical.com</p>
</div><p>Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.</p>
<div class="lb-trans"><p>經 AVITA Medical, Inc.首席財務官授權發佈。</p>
</div><p>©2026 AVITA Medical. AVITA Medical®, Cohealyx®, RECELL®, RECELL GO®, and Spray-On SkinTM are trademarks of AVITA Medical. PermeaDerm® is a registered trademark owned by Stedical Scientific, Inc. All other trademarks are the properties of their respective owners.</p>
<div class="lb-trans"><p>©2026 AVITA Medical。AVITA Medical®、Cohealyx®、RECELL®、RECELL GO®和噴霧皮膚 TM 是 AVITA Medical 的商標。PermeaDerm®是 Stedical Scientific, Inc.擁有的註冊商標。所有其他商標均為其各自所有者的財產。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU5ETTJOU00zTkRJMU1UVTJJekl4T0RFMU1UQT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY1NDM2NSM3NDI1MTU2IzIxODE1MTA="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2MzNTMyMDYtMmJjYS00N2JiLWFiNWYtNDQ5M2E4ZTk0MGI4LTExOTMwNzktMjAyNi0wMi0xMy1lbg==/tiny/AVITA-Medical.png" alt="" original-src="https://ml.globenewswire.com/media/M2MzNTMyMDYtMmJjYS00N2JiLWFiNWYtNDQ5M2E4ZTk0MGI4LTExOTMwNzktMjAyNi0wMi0xMy1lbg==/tiny/AVITA-Medical.png"/></p>

AVITA Medical 將舉辦投資者網絡研討會簡報 | RCEL 股票新聞